



Supplemental Figure 1




SUPPLEMENTARY DATA

Supplementary Figure 2. Plasma 3-H-glucose specific activity during Study 1 (A), Study 2 (B), and Study 3 (C) in subjects receiving dapagliflozin (closed circles) and placebo (open circles)


Supplemental Figure 2A



Supplemental Figure 2B




Supplemental Figure 2C



SUPPLEMENTARY DATA

Supplementary Figure 3. Total body endogenous glucose production (EGP) in dapagliflozin (left) or placebo (right) in Study 1, Study 2 (glucose clamp), and Study 3 (pancreatic clamp).


Supplemental Figure 3




SUPPLEMENTARY DATA

Supplementary Figure 4. Plasma glucagon concentration during Study 1 (EGP measurement) (A), Study 2 (glucose clamp) (B), and Study 3 (pancreatic clamp) (C) in subjects receiving 10 mg dapagliflozin (closed circles) 10 mg and placebo (open circles).


Supl Figure 4A: Glucagon-Study 1



Suppl Figure 4B:Glucagon-Study 2




Suppl Fig 4C: Glucagon-Study 3




SUPPLEMENTARY DATA

Supplementary Figure 5. Plasma insulin concentration during Study 1 (EGP measurement) (A), Study 2 (glucose clamp) (B), and Study 3 (pancreatic clamp) (C) in subjects receiving 10 mg dapagliflozin (closed circles) 10 mg and placebo (open circles).


Suppl Figure 5A: Insulin-Study 1



Suppl Figure 5B: Insulin- Study 2




Suppl Figure 5C: Insulin- Study 3




SUPPLEMENTARY DATA

Supplementary Figure 6. Plasma glucagon to insulin ratio during Study 1 (EGP measurement) (A), Study 2 (glucose clamp) (B), and Study 3 (pancreatic clamp) (C) in subjects receiving 10 mg dapagliflozin (closed circles) 10 mg and placebo (open circles).


Suppl Figure 6A



Suppl Figure 6B




Suppl Figure 6C




SUPPLEMENTARY DATA

Supplementary Figure 7. glucose infusion rate in Study 2 (glucose clamp) in subjects receiving placebo (open circles) and 10 mg dapagliflozin (closed circles) (A). the relationship between glucose infusion rate and urinary glucose excretion in subjects receiving dapagliflozin (10 mg) in Study 2 (glucose clamp).



Suppl Figure 7B



SUPPLEMENTARY DATA

Supplementary Figure 8. The difference between mean endogenous glucose production (EGP) in subjects receiving dapagliflozin and the mean EGP in subjects receiving placebo in Study 1, Study 2 (glucose clamp), and Study 3 (pancreatic clamp)

Supplemental Figure 8

